Ann Arbor, MI, AUGUST 3, 2021—Cayman Biomedical Research Institute (CABRI) is now accepting applications from undergraduate students who have been offered an unpaid laboratory research position under an accredited principal investigator. Applications will be accepted August 23 – September 19, 2021, for awards to be distributed by November 2, 2021. Grants range from $2,000 - $5,000 and may be awarded as individual or group grants.

“Because the research positions available to undergraduates do not typically come with a stipend, access to this important experience is limited to students who can afford to work without pay,” said Dr. Kirk Maxey, President and CEO of Cayman and President of CABRI. “Our grant is intended to expand access to this opportunity for more individuals whose early research training will set them on a lifelong path of scientific discovery. Also, we recognize that amid a global pandemic support for these students is even more crucial.”

As a business that provides the products to support essential research for human health and well-being, Cayman is here to help nurture the research community. CABRI is a 501(c)3 nonprofit affiliate of Cayman and is especially dedicated to supporting research for new treatments for rare cancers, orphan diseases, and genetic defects that are typically underfunded. Special consideration will be given to applications from students that work in laboratories aligning with this mission. Undergraduate grant applications may be submitted through this online form.

About CABRI
CABRI is a private foundation nonprofit located on the research campus of Cayman Chemical Company. Since our beginnings in 2005, we have been dedicated to helping those poorly served by the for-profit medical and pharmaceutical establishment. Our three main focal areas are:

• Rare disease research including:
• Congenital lamellar icththyosis Type I
• SNUC (sinonasal undifferentiated carcinoma)
  
• Mastocytosis
  
• Basic research support including PI grants, undergraduate work/study grants and research travel grants
  

CABRI is committed to researching, treating, and understanding rare cancers such as SNUC, orphan diseases and genetic defects. Many rare diseases remain without sufficient funding for research due to lack of awareness. CABRI is fighting to change this reality and extend compassionate support to those affected and their families. Our SNUC research is focused on studying the entire DNA composition of SNUC tumors to pinpoint each mutation and alteration with respect to the normal human sequence.

About Cayman Chemical
Cayman Chemical Company helps make research possible by supplying scientists worldwide with biochemical tools used to understand cancer, neurochemistry, oxidative injury, endocrinology, atherosclerosis, and other human health challenges. Our scientists are experts in the synthesis, purification, and characterization of biochemicals ranging from small drug-like heterocycles to complex biolipids, fatty acids, and many others for use as research reagents and qualified standards. We are also highly skilled in all aspects of assay and antibody development, protein expression, crystallization, and structure determination. In addition, Cayman Contract Services provides discovery and pre-clinical development services to the global pharmaceutical, biotechnology, and academic research markets. Our diverse suite of services leverages a team of over 150 highly skilled scientists with expertise in medicinal chemistry, structure-based drug design, complex multi-step organic synthesis, analytical chemistry, sample analysis, and custom assay development. Cayman performs generic drug development and production in both Ann Arbor, Michigan and Neratovice, Czech Republic.